. Author manuscript; available in PMC: 2022 Dec 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Dec 1;88(4):414–419. doi: 10.1097/QAI.0000000000002783

Table 1.

Demographics of cohort

	Controls, N=1509	PLWH CN, N=181	PLWH CI, N=116	p value
Age (years) , mean (SD)	45.4 ± 23.6	50.5 ± 12.9	44.6 ± 14.4	0.17
Sex (% Male)	62%	65%	69%	0.20
Education, mean (SD) (years)	14.1 ± 2.4	13.9 ± 2.4	13.7 ± 2.3	0.18
Race (% Caucasian)	79%	40%	27%	<0.001
Race (% African American)	10%	59%	73%	<0.001
Race (% Other)	11%	1%	0%	<0.001
Duration of Infection (years), mean (SD)		15.1 ± 8.2	15.1 ± 7.3	0.97
Current CD4 cells/μl, median (IQR)		595 (415)	614 (390)	0.31

SD=standard deviation, cART=combination antiretroviral therapy, IQR=interquartile range.